Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDD Plus Bortezomib vs CDD in Extramedullary Plasmacytoma
NCT02336386Phase 3Unknown
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in extramedullary plasmacytoma (EMP) (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Number of patients with overall hematologic response at 24 months. Status: unknown.
02
Drugs
bortezomib
03
Conditions
extramedullary plasmacytoma (EMP)
Beyond the preview
Go deeper on NCT02336386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336386.